Anglikon: Metformin Sustained-release Tablets with Sitagliptin Obtained Drug Registration Certificate

On July 31, AstraZeneca announced that the company has obtained the Drug Registration Certificate for the approval of saxagliptin metformin sustained-release tablets issued by the National Medical Products Administration. The saxagliptin metformin sustained-release tablet is a compound formulation suitable for adults with type 2 diabetes who are currently undergoing combined treatment with saxagliptin and metformin sustained-release tablets. The company received the Notice of Acceptance for the application for marketing approval of saxagliptin metformin sustained-release tablets in January 2024, and recently obtained approval from the National Medical Products Administration. According to relevant national policies, obtaining the Drug Registration Certificate this time is equivalent to passing consistency assessment.